L-carnitine L-tartrate
Term · Oncology and biomedicine · MLC-T-ONC-014725
A dietary supplement containing the levo-enantiomers of carnitine and tartrate with potential chemoprotective and antioxidant activities. L-carnitine L-tartrate increases fatty acid oxidation and reduces purine catabolism and free radical formation, which may prevent exercise fatigue, muscle weakness, chemotherapy-induced peripheral neuropathy, and hyperlipoproteinemia. L-carnitine, the biologically active form of carnitine, is a carrier molecule that transports activated long-chain fatty acids (LCFAs)from the cytosol to mitochondria where fatty acids are oxidized, resulting in ATP production,. L-tartrate, a salt of tartaric acid, is a potent antioxidant.
| Identifier | MLC-T-ONC-014725 |
|---|---|
| Field | Oncology and biomedicine |
| Abbreviation | LCLT |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-014725",
"term": "L-carnitine L-tartrate",
"field": "Oncology and biomedicine",
"definition": "A dietary supplement containing the levo-enantiomers of carnitine and tartrate with potential chemoprotective and antioxidant activities. L-carnitine L-tartrate increases fatty acid oxidation and reduces purine catabolism and free radical formation, which may prevent exercise fatigue, muscle weakness, chemotherapy-induced peripheral neuropathy, and hyperlipoproteinemia. L-carnitine, the biologically active form of carnitine, is a carrier molecule that transports activated long-chain fatty acids (LCFAs)from the cytosol to mitochondria where fatty acids are oxidized, resulting in ATP production,. L-tartrate, a salt of tartaric acid, is a potent antioxidant.",
"abbreviation": "LCLT",
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/l-carnitine-l-tartrate/"
}
Record 9,971 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.